Yew Bio-Pharm Welcomes Two New Board Members
HARBIN, China, July 15, 2014 /PRNewswire/ -- Yew Bio-Pharm Group, Inc. ("Yew Bio" or the "Company") (OTCBB: YEWB), a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine and products made from yew timber in China, today announced the appointment of Tong Liu and Hengjiang (Henry) Pang to the Company's Board of Directors, effective August 1, 2014.
"Tong and Henry are both excellent additions to our Board, with strong cross boarder experience and financial backgrounds," stated Zhiguo Wang, Chairman and Chief Executive Officer. "They will play an important role advising on the Company's growth strategy and efforts to enhance our presence in North America and operations in China."
Liu (34) is an investment banker with Los Angeles-based Diamond Capital Advisors where he specializes in cross-border transactions, focusing on the Greater China region. He holds FINRA Series 79 and 63 securities licenses. Prior to investment banking, Tong was a serial entrepreneur. He currently sits on the board of multiple startup companies.
Pang (33) serves as the North America Regional Manager for Yew Bio-Pharm Group, a position he has held since joining the Company in 2013. Prior to that, Pang served as Production Manager for HeJian Technology Co., Ltd., a subsidiary of United Microelectronics Corporation; Financial Controller for a private-equity company in the financial investment industry; and as Controller for Jellick Rowland LLC, a real estate investment company.
ABOUT YEW BIO-PHARM GROUP, INC.
Yew Bio-Pharm Group, Inc., through its operating entity, Harbin Yew Science and Technology Development Co., Ltd. (HDS), is a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine (TCM) and products made from yew timber in China. Raw material from the species of yew tree that the Company grows contains taxol, and TCM containing yew raw materials has been approved as a traditional Chinese medicine in China for secondary treatment of certain cancers. The Company uses a patented, accelerated growth technology to speed the growth and maturity and commercialization of yew trees and believes that it is one of the few companies possessing a permit to sell them. To learn more, please visit http://www.yewbiopharm.com/.
SOURCE Yew Bio-Pharm Group, Inc.